What type of study is this?

This is a Human Clinical Trial study (also classified as: RCT).

What question did this study set out to answer?

To determine the optimal dosing strategy of rituximab for preventing relapses in immune thrombotic thrombocytopaenic purpura (iTTP).

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Non-inferiority trial compares low versus standard dosing of rituximab in preventing relapses of immune TTP, indicating similar effectiveness.

To determine the optimal dosing strategy of rituximab for preventing relapses in immune thrombotic thrombocytopaenic purpura (iTTP).
Conducted a randomised single-blind non-inferiority trial in UK hospitals
Patients with known iTTP assigned to low-dose or standard-dose rituximab
Primary outcome measured was time to retreatment with RTX or other immunosuppression
No significant difference in median time to retreatment with low dose (19.7 months) vs standard dose (20.1 months)
Low dose RTX had 6.3% relapse rate compared to 0% for standard dose
Both dosing regimens demonstrated similar rates of B cell depletion and adverse effects

Clark et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Non-inferiority trial compares low versus standard dosing of rituximab in preventing relapses of immune TTP, indicating similar effectiveness.